Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been studied for their potential antiarrhythmic effects. Early observational studies suggested that populations with higher fish consumption had lower rates of sudden cardiac death, which is often attributed to arrhythmias. Several mechanistic studies have shown that omega-3 fatty acids can modulate cardiac ion channels, reduce myocardial excitability, and lower the risk of abnormal electrical activity in heart tissue. This provided a biological rationale for their use in arrhythmia prevention and management.

Randomized controlled trials (RCTs), however, have produced mixed results. Some earlier trials, like the GISSI-Prevenzione trial, found a reduction in sudden cardiac death among post-myocardial infarction patients supplemented with omega-3s. Subsequent studies, such as the OMEGA and Alpha Omega trials, did not replicate these findings. More recent meta-analyses suggest a possible modest benefit in reducing the risk of arrhythmias, particularly in individuals with existing heart disease, but the effect is not consistent across all populations or types of arrhythmia (e.g., atrial vs. ventricular).

Current guidelines suggest that while omega-3 supplementation may be considered in select patients, especially those with documented coronary heart disease, it should not replace standard antiarrhythmic therapy. Overall, the evidence base is substantial but not uniformly positive, justifying a moderate rating for scientific support.

More about omega-3 fatty acids
More about Arrhythmia

Other ingredients used for Arrhythmia

Other health conditions supported by omega-3 fatty acids

Products containing omega-3 fatty acids

Nature's Sunshine Flax Seed Oil (With Lignans)